Development of a dry powder formulation for pulmonary delivery of azithromycin-loaded nanoparticles DOI Creative Commons
Asma Sani,

Khellida Loiane V. Ramos-Rocha,

Michelle Alvares Sarcinelli

et al.

Journal of Pharmacy & Pharmaceutical Sciences, Journal Year: 2024, Volume and Issue: 27

Published: Oct. 14, 2024

The COVID-19 pandemic has raised concern regarding respiratory system diseases and oral inhalation stands out as an attractive non-invasive route of administration for pulmonary such chronic bronchitis, cystic fibrosis, community-acquired pneumonia. In this context, we encapsulated azithromycin in polycaprolactone nanoparticles functionalized with phospholipids rich dipalmitoylphosphatidylcholine further produced a fine powder formulation by spray drying monohydrated lactose. Nanoparticles obtained the emulsion/solvent diffusion-evaporation technique exhibited mean hydrodynamic diameter around 195–228 nm narrow monomodal size distribution (PdI < 0.2). Nanoparticle dispersions were spray-dried at different inlet temperatures, atomizing air-flow, aspirator air flow, feed rate, using lactose aid, resulting maximal process yield 63% encapsulation efficiency 83%. Excipients dry formulations characterized terms morphology, chemical structure, thermal analyses particle SEM, FTIR, DSC/TGA laser light diffraction. results indicated spherical particles 90% 4.06 µm or below, adequate delivery. Aerosolization performance NGI confirmed good aerodynamic properties. Microbiological assays showed that preserves AZM antimicrobial effect against Staphylococcus aureus Streptococcus pneumoniae strains, halos above 18 mm. addition, no formulation-related cytotoxicity was observed human cell lines BEAS-2B (lung epithelial), HUVEC (endothelial) HFF1 (fibroblasts). Overall, approach described here allows production AZM-PCL incorporated into inhalable microparticles, enabling more efficient therapy lung infections.

Language: Английский

Development of a dry powder formulation for pulmonary delivery of azithromycin-loaded nanoparticles DOI Creative Commons
Asma Sani,

Khellida Loiane V. Ramos-Rocha,

Michelle Alvares Sarcinelli

et al.

Journal of Pharmacy & Pharmaceutical Sciences, Journal Year: 2024, Volume and Issue: 27

Published: Oct. 14, 2024

The COVID-19 pandemic has raised concern regarding respiratory system diseases and oral inhalation stands out as an attractive non-invasive route of administration for pulmonary such chronic bronchitis, cystic fibrosis, community-acquired pneumonia. In this context, we encapsulated azithromycin in polycaprolactone nanoparticles functionalized with phospholipids rich dipalmitoylphosphatidylcholine further produced a fine powder formulation by spray drying monohydrated lactose. Nanoparticles obtained the emulsion/solvent diffusion-evaporation technique exhibited mean hydrodynamic diameter around 195–228 nm narrow monomodal size distribution (PdI < 0.2). Nanoparticle dispersions were spray-dried at different inlet temperatures, atomizing air-flow, aspirator air flow, feed rate, using lactose aid, resulting maximal process yield 63% encapsulation efficiency 83%. Excipients dry formulations characterized terms morphology, chemical structure, thermal analyses particle SEM, FTIR, DSC/TGA laser light diffraction. results indicated spherical particles 90% 4.06 µm or below, adequate delivery. Aerosolization performance NGI confirmed good aerodynamic properties. Microbiological assays showed that preserves AZM antimicrobial effect against Staphylococcus aureus Streptococcus pneumoniae strains, halos above 18 mm. addition, no formulation-related cytotoxicity was observed human cell lines BEAS-2B (lung epithelial), HUVEC (endothelial) HFF1 (fibroblasts). Overall, approach described here allows production AZM-PCL incorporated into inhalable microparticles, enabling more efficient therapy lung infections.

Language: Английский

Citations

2